Patents by Inventor Ivy Foo-Hurwitz

Ivy Foo-Hurwitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240081341
    Abstract: The present invention describes capsule compositions consisting of crosslinked chitosan, beta-glucan or alginate, and encapsulates an environmentally compatible insecticide, especially larvicidal agents such as essential oils or essential oil components or other ingestible larvicides such as Bacillus thuringiensis which are lethal to the larvae and adults of pest insects, especially mosquito larvae.
    Type: Application
    Filed: October 23, 2023
    Publication date: March 14, 2024
    Inventors: Alexandra Victoria Yingling, Ivy Foo-Hurwitz, Linnea Ista, Scott Matthews, Fernando Genta, Bruno Gomes
  • Publication number: 20240041029
    Abstract: The present invention describes capsule compositions consisting of crosslinked chitosan, beta-glucan or alginate, and encapsulates an environmentally compatible ingestible larvicide, especially larvicidal agents such as essential oils or other ingestible larvicides such as Bacillus thuringiensis which are lethal to the larvae of pest insects, especially mosquito larvae.
    Type: Application
    Filed: September 8, 2021
    Publication date: February 8, 2024
    Inventors: Alexandra Victoria Yingling, Ivy Foo-Hurwitz, Linnea Ista, Scott Matthews, Fernando Genta, Bruno Gomes
  • Patent number: 11337422
    Abstract: A larvicide comprising an essential oil encapsulated within a non-viable yeast cell. The larvicide is particularly effective against mosquito larvae, non-toxic to humans and other non-target species, inexpensive to make, and non-toxic during manufacture, transport, and storage.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 24, 2022
    Assignee: UNM Rainforest Innovations
    Inventors: Ivy Foo-Hurwitz, Ravi Durvasula, Scott Matthews, Michael Workman
  • Patent number: 10555519
    Abstract: An larvicide comprising an essential oil encapsulated within a non-viable yeast cell. The larvicide is particularly effective against mosquito larvae, non-toxic to humans and other non-target species, inexpensive to make, and non-toxic during manufacture, transport, and storage.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: February 11, 2020
    Assignee: STC.UNM
    Inventors: Scott Matthews, Ravi Durvasula, Ivy Foo-Hurwitz
  • Publication number: 20200015477
    Abstract: A larvicide comprising an essential oil encapsulated within a non-viable yeast cell. The larvicide is particularly effective against mosquito larvae, non-toxic to humans and other non-target species, inexpensive to make, and non-toxic during manufacture, transport, and storage.
    Type: Application
    Filed: July 24, 2019
    Publication date: January 16, 2020
    Applicant: STC.UNM
    Inventors: Ivy Foo-Hurwitz, Ravi Durvasula, Scott Matthews, Michael Workman
  • Publication number: 20190359695
    Abstract: In one aspect, a fusion antibody specifically binds to a C. difficile virulence toxin. In some embodiments, the C. difficile virulence toxin can include TcdA or TcdB. In some embodiments, the fusion antibody can include a first antibody moiety and a second antibody moiety. The first antibody moiety can include at least a fragment of a first antibody, and the second antibody moiety can include at least a fragment of a second antibody. In another aspect, a recombinant cell expresses the fusion antibody. In another aspect, a recombinant cell has activity that can be modulated by growing the recombinant cell in medium that includes cellobiose. Generally, the recombinant cell includes a heterologous polynucleotide that includes a promoter operably linked to a heterologous coding region, wherein the expression from the promoter is modulated when the recombinant cell is grown in culture medium that comprises cellobiose compared to when the recombinant cell is grown in culture medium that comprises glucose.
    Type: Application
    Filed: February 9, 2018
    Publication date: November 28, 2019
    Inventors: Ravi Venkata Durvasula, Ivy Foo-Hurwitz, Qiuying Cheng, Christian Ogaugwo